Suppr超能文献

一名合并B细胞淋巴瘤的COVID-19患者通过联合使用阿育吠陀配方药物进行治疗。

COVID-19 patient with B cell lymphoma co-morbidity managed with co-administration of ayurvedic formulation.

作者信息

Dilip Pandkar Prasad, Deshmukh Santosh Raosaheb, Sachdeva Vinay

机构信息

Department of Kriya sharir (Ayurveda Physiology), Bharati Vidyapeeth Deemed University, College of Ayurveda, Pune, 411043, India.

Shri Vishwavati Ayurvedic Chikitsalay and Research Centre, Kolhapur, Maharashtra, India.

出版信息

J Ayurveda Integr Med. 2022 Jul-Sep;13(3):100632. doi: 10.1016/j.jaim.2022.100632. Epub 2022 Aug 12.

Abstract

'Renaissance took place in Chaos and plague'. It was COVID-19 pandemic, when world realized ayurveda co-interventions are praiseworthy even in acute, infective and fatal conditions like COVID-19. We report perhaps first case of COVID-19 patient with cancer managed with poly-herbal ayurvedic formulation and integrated approach. In the first wave of COVID-19 (June 2020), a 47 year old male with history of Chronic kidney disease and active B Cell Lymphoma complained of fever, malaise, cattarah and ageusia. He was found positive on RT-PCR which was done promptly and was later treated in home quarantine with antipyretics, Vitamin C and Madhav rasayan a polyherbal preparation containing , , , , and designed to modulate host response. It was challenging to treat a patient with cancer with immunocompromised status as he had recently finished his chemotherapy cycle (R-CHOP regimen). Patient well tolerated the intervention and recovered symptomatically. He did not developed any respiratory complications and oxygen saturation remained maintained. On 7th day RT-PCR was found to be negative. Plethora of literature is available on anti-viral and immunomodulatory efficacies of Ayurveda herbs based on in vitro studies. Such efficacies can be replicated at patient's level if supported with wisdom of Ayurveda epistemology. Early diagnosis on RT-PCR and early inception of ayurveda medicine and diet interventions might be crucial element for better recovery.

摘要

“复兴在混乱和瘟疫中发生”。正是在新冠疫情期间,全世界意识到阿育吠陀辅助干预措施即使在像新冠这样的急性、感染性和致命疾病中也值得称赞。我们报告了或许首例采用多草药阿育吠陀配方和综合方法治疗的新冠合并癌症患者。在新冠疫情的第一波(2020年6月)中,一名患有慢性肾病且患有活跃B细胞淋巴瘤的47岁男性出现发热、不适、卡他症状和味觉丧失。他的逆转录聚合酶链反应(RT-PCR)检测呈阳性,检测迅速进行,随后在家中隔离,接受退烧药、维生素C和玛德哈夫拉萨扬(Madhav rasayan)治疗,玛德哈夫拉萨扬是一种多草药制剂,含有[此处原文缺失部分草药名称],旨在调节宿主反应。治疗一名处于免疫功能低下状态的癌症患者具有挑战性,因为他最近刚完成化疗周期(R-CHOP方案)。患者对干预措施耐受性良好,症状得到缓解。他没有出现任何呼吸道并发症,血氧饱和度保持稳定。在第7天,RT-PCR检测结果为阴性。基于体外研究,有大量关于阿育吠陀草药抗病毒和免疫调节功效的文献。如果有阿育吠陀认识论的智慧支持,这些功效可以在患者层面得到复制。RT-PCR早期诊断以及阿育吠陀药物和饮食干预的早期启动可能是更好康复的关键因素。

相似文献

9
Ayurvedic treatment of COVID-19: A case report.阿育吠陀疗法治疗新冠肺炎:一例病例报告。
J Ayurveda Integr Med. 2022 Jan-Mar;13(1):100329. doi: 10.1016/j.jaim.2020.06.001. Epub 2020 Jun 19.

本文引用的文献

6
Pathophysiology of Covid-19 and host centric approaches in .新冠病毒病的病理生理学及以宿主为中心的方法
J Ayurveda Integr Med. 2022 Jan-Mar;13(1):100380. doi: 10.1016/j.jaim.2020.11.010. Epub 2020 Dec 2.
8
The role of dysregulated immune responses in COVID-19 pathogenesis.免疫应答失调在 COVID-19 发病机制中的作用。
Virus Res. 2020 Dec;290:198197. doi: 10.1016/j.virusres.2020.198197. Epub 2020 Oct 16.
10
Ayurvedic clinical profile of COVID-19 - A preliminary report.COVID-19的阿育吠陀临床概况——初步报告。
J Ayurveda Integr Med. 2022 Jan-Mar;13(1):100326. doi: 10.1016/j.jaim.2020.05.011. Epub 2020 Jun 12.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验